Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H.

Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22.

PMID:
31011202
2.

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.

Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.

PMID:
30413523
3.

The functional impact of variants of uncertain significance in BRCA2.

Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, van Asperen CJ, Vrieling H, Vreeswijk MPG.

Genet Med. 2019 Feb;21(2):293-302. doi: 10.1038/s41436-018-0052-2. Epub 2018 Jul 10.

PMID:
29988080
4.

Adverse outcome pathways: opportunities, limitations and open questions.

Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH, Limonciel A, Vinken M, Schildknecht S, Waldmann T, Danen E, van Ravenzwaay B, Kamp H, Gardner I, Godoy P, Bois FY, Braeuning A, Reif R, Oesch F, Drasdo D, Höhme S, Schwarz M, Hartung T, Braunbeck T, Beltman J, Vrieling H, Sanz F, Forsby A, Gadaleta D, Fisher C, Kelm J, Fluri D, Ecker G, Zdrazil B, Terron A, Jennings P, van der Burg B, Dooley S, Meijer AH, Willighagen E, Martens M, Evelo C, Mombelli E, Taboureau O, Mantovani A, Hardy B, Koch B, Escher S, van Thriel C, Cadenas C, Kroese D, van de Water B, Hengstler JG.

Arch Toxicol. 2017 Nov;91(11):3477-3505. doi: 10.1007/s00204-017-2045-3. Epub 2017 Oct 19. Review.

PMID:
29051992
5.

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.

Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calléja FMGR, Meeks H, Hallberg E, Hinton J, Lilyquist J, Hu C, Aalfs CM, Aittomäki K, Andrulis I, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Brauch H, Brennan P, Brenner H, Broeks A, Brouwers B, Brüning T, Burwinkel B, Chang-Claude J, Chenevix-Trench G, Cheng CY, Choi JY, Collée JM, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Dörk T, Dos-Santos-Silva I, Dunning AM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Guénel P, Haiman CA, Hall P, Hamann U, Hartman M, Hogervorst FB, Hollestelle A, Hopper JL, Ito H, Jakubowska A, Kang D, Kosma VM, Kristensen V, Lai KN, Lambrechts D, Marchand LL, Li J, Lindblom A, Lophatananon A, Lubinski J, Machackova E, Mannermaa A, Margolin S, Marme F, Matsuo K, Miao H, Michailidou K, Milne RL, Muir K, Neuhausen SL, Nevanlinna H, Olson JE, Olswold C, Oosterwijk JJC, Osorio A, Peterlongo P, Peto J, Pharoah PDP, Pylkäs K, Radice P, Rashid MU, Rhenius V, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schoemaker MJ, Seynaeve C, Shah M, Shen CY, Shrubsole M, Shu XO, Slager S, Southey MC, Stram DO, Swerdlow A, Teo SH, Tomlinson I, Torres D, Truong T, van Asperen CJ, van der Kolk LE, Wang Q, Winqvist R, Wu AH, Yu JC, Zheng W, Zheng Y, Leary J, Walker L, Foretova L, Fostira F, Claes KBM, Varesco L, Moghadasi S, Easton DF, Spurdle A, Devilee P, Vrieling H, Monteiro ANA, Goldgar DE, Carreira A, Vreeswijk MPG, Couch FJ; for kConFab/AOCS Investigators; for NBCS Collaborators.

Cancer Res. 2017 Jun 1;77(11):2789-2799. doi: 10.1158/0008-5472.CAN-16-2568. Epub 2017 Mar 10.

6.

Prostate Cancer Patients with Late Radiation Toxicity Exhibit Reduced Expression of Genes Involved in DNA Double-Strand Break Repair and Homologous Recombination.

van Oorschot B, Uitterhoeve L, Oomen I, Ten Cate R, Medema JP, Vrieling H, Stalpers LJ, Moerland PD, Franken NA.

Cancer Res. 2017 Mar 15;77(6):1485-1491. doi: 10.1158/0008-5472.CAN-16-1966. Epub 2017 Jan 20.

7.

Xenobiotic metabolism in differentiated human bronchial epithelial cells.

Boei JJWA, Vermeulen S, Klein B, Hiemstra PS, Verhoosel RM, Jennen DGJ, Lahoz A, Gmuender H, Vrieling H.

Arch Toxicol. 2017 May;91(5):2093-2105. doi: 10.1007/s00204-016-1868-7. Epub 2016 Oct 13.

8.

The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding.

Hendriks G, Derr RS, Misovic B, Morolli B, Calléja FM, Vrieling H.

Toxicol Sci. 2016 Mar;150(1):190-203. doi: 10.1093/toxsci/kfv323. Epub 2015 Dec 29.

9.

Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-κB activation and sensitizes toward TNFα-induced cytotoxicity.

Herpers B, Wink S, Fredriksson L, Di Z, Hendriks G, Vrieling H, de Bont H, van de Water B.

Arch Toxicol. 2016 May;90(5):1163-79. doi: 10.1007/s00204-015-1536-3. Epub 2015 May 31.

10.

Deciphering the RNA landscape by RNAome sequencing.

Derks KW, Misovic B, van den Hout MC, Kockx CE, Gomez CP, Brouwer RW, Vrieling H, Hoeijmakers JH, van IJcken WF, Pothof J.

RNA Biol. 2015;12(1):30-42. doi: 10.1080/15476286.2015.1017202.

11.

The E3 ubiquitin ligase ARIH1 protects against genotoxic stress by initiating a 4EHP-mediated mRNA translation arrest.

von Stechow L, Typas D, Carreras Puigvert J, Oort L, Siddappa R, Pines A, Vrieling H, van de Water B, Mullenders LH, Danen EH.

Mol Cell Biol. 2015 Apr;35(7):1254-68. doi: 10.1128/MCB.01152-14. Epub 2015 Jan 26.

12.

Mechanism-based genotoxicity screening of metal oxide nanoparticles using the ToxTracker panel of reporter cell lines.

Karlsson HL, Gliga AR, Calléja FM, Gonçalves CS, Wallinder IO, Vrieling H, Fadeel B, Hendriks G.

Part Fibre Toxicol. 2014 Sep 2;11:41. doi: 10.1186/s12989-014-0041-9.

13.

An efficient pipeline for the generation and functional analysis of human BRCA2 variants of uncertain significance.

Hendriks G, Morolli B, Calléja FM, Plomp A, Mesman RL, Meijers M, Sharan SK, Vreeswijk MP, Vrieling H.

Hum Mutat. 2014 Nov;35(11):1382-91. doi: 10.1002/humu.22678. Epub 2014 Sep 11.

PMID:
25146914
14.

Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.

Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC.

Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24.

15.

Buccal and sublingual vaccine delivery.

Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij JP.

J Control Release. 2014 Sep 28;190:580-92. doi: 10.1016/j.jconrel.2014.05.060. Epub 2014 Jun 6. Review.

16.

Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment.

Wink S, Hiemstra S, Huppelschoten S, Danen E, Niemeijer M, Hendriks G, Vrieling H, Herpers B, van de Water B.

Chem Res Toxicol. 2014 Mar 17;27(3):338-55. doi: 10.1021/tx4004038. Epub 2014 Feb 5. Review.

PMID:
24450961
17.

Reduced activity of double-strand break repair genes in prostate cancer patients with late normal tissue radiation toxicity.

van Oorschot B, Hovingh SE, Moerland PD, Medema JP, Stalpers LJ, Vrieling H, Franken NA.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):664-70. doi: 10.1016/j.ijrobp.2013.11.219. Epub 2014 Jan 8.

PMID:
24411188
18.

Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2.

Zweemer AJ, Nederpelt I, Vrieling H, Hafith S, Doornbos ML, de Vries H, Abt J, Gross R, Stamos D, Saunders J, Smit MJ, Ijzerman AP, Heitman LH.

Mol Pharmacol. 2013 Oct;84(4):551-61. doi: 10.1124/mol.113.086850. Epub 2013 Jul 22.

PMID:
23877010
19.

Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients.

Hameetman L, Commandeur S, Bavinck JN, Wisgerhof HC, de Gruijl FR, Willemze R, Mullenders L, Tensen CP, Vrieling H.

BMC Cancer. 2013 Feb 5;13:58. doi: 10.1186/1471-2407-13-58.

20.

Systems biology approach identifies the kinase Csnk1a1 as a regulator of the DNA damage response in embryonic stem cells.

Carreras Puigvert J, von Stechow L, Siddappa R, Pines A, Bahjat M, Haazen LC, Olsen JV, Vrieling H, Meerman JH, Mullenders LH, van de Water B, Danen EH.

Sci Signal. 2013 Jan 22;6(259):ra5. doi: 10.1126/scisignal.2003208.

PMID:
23354688
21.

Cellular-signaling pathways unveil the carcinogenic potential of chemicals.

Hendriks G, van de Water B, Schoonen W, Vrieling H.

J Appl Toxicol. 2013 Jun;33(6):399-409. doi: 10.1002/jat.2845. Epub 2013 Jan 22. Review.

PMID:
23339022
22.

PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1.

Pines A, Vrouwe MG, Marteijn JA, Typas D, Luijsterburg MS, Cansoy M, Hensbergen P, Deelder A, de Groot A, Matsumoto S, Sugasawa K, Thoma N, Vermeulen W, Vrieling H, Mullenders L.

J Cell Biol. 2012 Oct 15;199(2):235-49. doi: 10.1083/jcb.201112132. Epub 2012 Oct 8.

23.

No threshold for the induction of chromosomal damage at clinically relevant low doses of X rays.

Boei JJ, Vermeulen S, Skubakova MM, Meijers M, Loenen WA, Wolterbeek R, Mullenders LH, Vrieling H, Giphart-Gassler M.

Radiat Res. 2012 May;177(5):602-13. Epub 2012 Apr 2.

PMID:
22468706
24.

Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells.

Pines A, Kelstrup CD, Vrouwe MG, Puigvert JC, Typas D, Misovic B, de Groot A, von Stechow L, van de Water B, Danen EH, Vrieling H, Mullenders LH, Olsen JV.

Mol Cell Biol. 2011 Dec;31(24):4964-77. doi: 10.1128/MCB.05258-11. Epub 2011 Oct 17.

25.

The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals.

Hendriks G, Atallah M, Morolli B, Calléja F, Ras-Verloop N, Huijskens I, Raamsman M, van de Water B, Vrieling H.

Toxicol Sci. 2012 Jan;125(1):285-98. doi: 10.1093/toxsci/kfr281. Epub 2011 Oct 14.

PMID:
22003191
26.

Sensitive DsRed fluorescence-based reporter cell systems for genotoxicity and oxidative stress assessment.

Hendriks G, Atallah M, Raamsman M, Morolli B, van der Putten H, Jaadar H, Tijdens I, Esveldt-van Lange R, Mullenders L, van de Water B, Vrieling H.

Mutat Res. 2011 May 10;709-710:49-59. doi: 10.1016/j.mrfmmm.2011.02.013. Epub 2011 Mar 4.

PMID:
21382384
27.

Enhanced global genome nucleotide excision repair reduces UV carcinogenesis and nullifies strand bias in p53 mutations in Csb-/- mice.

Pines A, Hameetman L, de Wilde J, Alekseev S, de Gruijl FR, Vrieling H, Mullenders LH.

J Invest Dermatol. 2010 Jun;130(6):1746-9. doi: 10.1038/jid.2010.18. Epub 2010 Feb 11. No abstract available.

28.

Transcription-dependent cytosine deamination is a novel mechanism in ultraviolet light-induced mutagenesis.

Hendriks G, Calléja F, Besaratinia A, Vrieling H, Pfeifer GP, Mullenders LH, Jansen JG, de Wind N.

Curr Biol. 2010 Jan 26;20(2):170-5. doi: 10.1016/j.cub.2009.11.061. Epub 2009 Dec 31.

29.

Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.

Silva FP, Almeida I, Morolli B, Brouwer-Mandema G, Wessels H, Vossen R, Vrieling H, Marijt EW, Valk PJ, Kluin-Nelemans HC, Sperr WR, Ludwig WD, Giphart-Gassler M.

Haematologica. 2009 Nov;94(11):1546-54. doi: 10.3324/haematol.2009.009324. Epub 2009 Sep 22.

30.

Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models.

Jonker MJ, Bruning O, van Iterson M, Schaap MM, van der Hoeven TV, Vrieling H, Beems RB, de Vries A, van Steeg H, Breit TM, Luijten M.

Carcinogenesis. 2009 Oct;30(10):1805-12. doi: 10.1093/carcin/bgp190. Epub 2009 Aug 20.

PMID:
19696161
31.

Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status.

Silva FP, Swagemakers SM, Erpelinck-Verschueren C, Wouters BJ, Delwel R, Vrieling H, van der Spek P, Valk PJ, Giphart-Gassler M.

Blood. 2009 Oct 1;114(14):3001-7. doi: 10.1182/blood-2009-03-211334. Epub 2009 Aug 7.

32.

Site-specific analysis of UV-induced cyclobutane pyrimidine dimers in nucleotide excision repair-proficient and -deficient hamster cells: Lack of correlation with mutational spectra.

Vreeswijk MP, Meijers CM, Giphart-Gassler M, Vrieling H, van Zeeland AA, Mullenders LH, Loenen WA.

Mutat Res. 2009 Apr 26;663(1-2):7-14. doi: 10.1016/j.mrfmmm.2008.12.007. Epub 2008 Dec 27.

PMID:
19150617
33.

Differential activity of UV-DDB in mouse keratinocytes and fibroblasts: impact on DNA repair and UV-induced skin cancer.

Pines A, Backendorf C, Alekseev S, Jansen JG, de Gruijl FR, Vrieling H, Mullenders LH.

DNA Repair (Amst). 2009 Feb 1;8(2):153-61. doi: 10.1016/j.dnarep.2008.09.011. Epub 2008 Dec 4.

PMID:
18996499
34.

Cell-type-specific consequences of nucleotide excision repair deficiencies: Embryonic stem cells versus fibroblasts.

de Waard H, Sonneveld E, de Wit J, Esveldt-van Lange R, Hoeijmakers JH, Vrieling H, van der Horst GT.

DNA Repair (Amst). 2008 Oct 1;7(10):1659-69. doi: 10.1016/j.dnarep.2008.06.009. Epub 2008 Jul 26.

PMID:
18634906
35.

Gene transcription increases DNA damage-induced mutagenesis in mammalian stem cells.

Hendriks G, Calléja F, Vrieling H, Mullenders LH, Jansen JG, de Wind N.

DNA Repair (Amst). 2008 Aug 2;7(8):1330-9. doi: 10.1016/j.dnarep.2008.04.015. Epub 2008 Jun 9.

PMID:
18539547
36.

ETV6 mutations and loss in AML-M0.

Silva FP, Morolli B, Storlazzi CT, Zagaria A, Impera L, Klein B, Vrieling H, Kluin-Nelemans HC, Giphart-Gassler M.

Leukemia. 2008 Aug;22(8):1639-43. doi: 10.1038/leu.2008.34. Epub 2008 Feb 28. No abstract available.

PMID:
18305557
37.

A validation of 10 feline reference genes for gene expression measurements in snap-frozen tissues.

Penning LC, Vrieling HE, Brinkhof B, Riemers FM, Rothuizen J, Rutteman GR, Hazewinkel HA.

Vet Immunol Immunopathol. 2007 Dec 15;120(3-4):212-22. Epub 2007 Aug 15.

PMID:
17904230
38.

[Report of the 2nd WVT-symposium].

Vrieling H.

Tijdschr Diergeneeskd. 2007 Jan 1;132(1):979-80. Dutch. No abstract available.

PMID:
17334109
39.

A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response.

Kruse JJ, Svensson JP, Huigsloot M, Giphart-Gassler M, Schoonen WG, Polman JE, Jean Horbach G, van de Water B, Vrieling H.

Mutat Res. 2007 Apr 1;617(1-2):58-70. Epub 2007 Feb 2.

PMID:
17327130
40.

Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity.

Svensson JP, Stalpers LJ, Esveldt-van Lange RE, Franken NA, Haveman J, Klein B, Turesson I, Vrieling H, Giphart-Gassler M.

PLoS Med. 2006 Oct;3(10):e422.

41.

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.

van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CW.

J Bone Miner Res. 2007 Jan;22(1):19-28.

42.

Meeting report. Second EU-US workshop on systems level understanding of DNA damage responses.

Sander M, Desaintes C, Ferro W, Mullenders L, Vrieling H, Pelroy R, Van Houten B, Wallace S.

Mutat Res. 2006 Jul 25;599(1-2):178-204. No abstract available.

PMID:
16929562
43.

Nucleotide excision repair in differentiated cells.

van der Wees C, Jansen J, Vrieling H, van der Laarse A, Van Zeeland A, Mullenders L.

Mutat Res. 2007 Jan 3;614(1-2):16-23. Epub 2006 Aug 1. Review.

PMID:
16879838
44.

[Pet program for the Voorjaarsdagen].

Vrieling H.

Tijdschr Diergeneeskd. 2006 May 15;131(10):377-8. Dutch. No abstract available.

PMID:
16736651
45.

Enhanced DDB2 expression protects mice from carcinogenic effects of chronic UV-B irradiation.

Alekseev S, Kool H, Rebel H, Fousteri M, Moser J, Backendorf C, de Gruijl FR, Vrieling H, Mullenders LH.

Cancer Res. 2005 Nov 15;65(22):10298-306.

46.

[Cats with feline odontoclastic resorptive lesions (FORL)].

Vrieling HE.

Tijdschr Diergeneeskd. 2005 Sep 1;130(17):533. Dutch. No abstract available.

PMID:
16173629
47.

Dissecting systems-wide data using mixture models: application to identify affected cellular processes.

Svensson JP, de Menezes RX, Turesson I, Giphart-Gassler M, Vrieling H.

BMC Bioinformatics. 2005 Jul 14;6:177.

48.

Transcription-coupled repair: impact on UV-induced mutagenesis in cultured rodent cells and mouse skin tumors.

van Zeeland AA, Vreeswijk MP, de Gruijl FR, van Kranen HJ, Vrieling H, Mullenders LF.

Mutat Res. 2005 Sep 4;577(1-2):170-8. Review.

PMID:
15949822
49.

The UV-damaged DNA binding protein mediates efficient targeting of the nucleotide excision repair complex to UV-induced photo lesions.

Moser J, Volker M, Kool H, Alekseev S, Vrieling H, Yasui A, van Zeeland AA, Mullenders LH.

DNA Repair (Amst). 2005 May 2;4(5):571-82.

PMID:
15811629
50.

[Effectiveness of feeding large kibbles with mechanical cleaning properties in cats with gingivitis].

Vrieling HE, Theyse LF, van Winkelhoff AJ, Dijkshoorn NA, Logan EI, Picavet P.

Tijdschr Diergeneeskd. 2005 Mar 1;130(5):136-40. Dutch.

PMID:
15773760

Supplemental Content

Loading ...
Support Center